利拉鲁肽注射液对2型糖尿病合并非酒精性脂肪肝患者内质网应激的影响及其疗效分析

肝脏 ›› 2020, Vol. 25 ›› Issue (9): 972-974.

利拉鲁肽注射液对2型糖尿病合并非酒精性脂肪肝患者内质网应激的影响及其疗效分析

高兰, 刘海蔚, 林璐, 陈开宁

570100 海口海南省人民医院内分泌科

出版日期:2020-09-30 发布日期:2020-10-22
通讯作者: 陈开宁
基金资助:
2018年海南省医药卫生科研项目(A2018-14)

Effect of Liraglutide on ERS in T2DM and NAFLD patients and its clinic efficacy

GAO Lan, LIU Hai-wei, LIN Lu, CHEN Kai-ning

Department of Endocrinology, Hainan People's Hospital, Haikou, 570100, China

Online:2020-09-30 Published:2020-10-22
Contact: CHEN Kai-ning

摘要/Abstract

摘要： 目的观察利拉鲁肽对2型糖尿病(T2DM)合并非酒精性脂肪肝(NAFLD)患者内质网应激(ERS)的影响,并分析其临床疗效。方法选取我院2017年6月—2019年2月收治的T2DM伴发NAFLD患者144例,使用数字表法随机分为对照组和观察组,每组72例。对照组给二甲双胍,0.5g/次,2次/d,观察组给予利拉鲁肽,0.6mg/d,连用1周,以后1.2 mg/d,疗程12周。使用荧光定量PCR法检测内质网应激蛋白( CHOP)、激活转录因子 6(ATF6) 和分子伴侣葡萄糖调节蛋白78(GRP78)基因表达。比较两组临床疗效和不良反应。结果治疗前两组FBG、2 h PBG、HbA1c、HOMA-IR、TG、TC和LDL-C无显著性差异(P>0.05),治疗后观察组FBG、2 h PBG、HbA1c、HOMA-IR、TG、TC和LDL-C显著低于对照组(P<0.05)。治疗前两组CHOP、ATF6和GRP78基因表达2^-△△Ct值无显著性差异(P>0.05),治疗后观察组CHOP、ATF6和GRP78基因表达2^-△△Ct值显著低于对照组(P<0.05)。观察组临床治疗有效率为81.9%(59/72),显著高于对照组的62.5%(45/72)(P<0.05)。对照组不良反应发生率为2.8%(2/72),观察组不良反应发生率为4.2%(3/72),两组不良反应发生率无显著性差异(P>0.05)。结论利拉鲁肽可以降低T2DM伴发NAFLD患者的ERS,降低血糖和血脂,临床疗效显著,使用安全。

关键词: 利拉鲁肽, 2型糖尿病, 非酒精性脂肪肝, 内质网应激

Abstract: Objective To detect the effect of Liraglutide on endoplasmic reticulum stress (ERS) in type 2 diabetes mellitus(T2DM) and non-alcoholic fatty liver disease(NAFLD) patients and analyze its clinic efficacy. Methods A total of 144 patients were enrolled in this study. Who were divided into: control group(n=72) and observation group(n=72). The control group was given metformin(0.5 g/time, 2 times/d for 12 weeks). The observation group was given Liraglutide (0.6 mg/d for 1 weeks, 1.2 mg/d for 11 weeks ). CHOP, ATF6, and GRP78 mRNA expression was detected by realtime PCR. The clinical efficacy and adverse reactions rate was compared. Results After treatment, the expression of FBG, 2hPBG, HbA1c, HOMA-IR, TG, TC, and LDL-C was significantly lower in observation group than that in control group (P<0.05). The 2^-△△Ct values of CHOP, ATF6, and GRP78 was significantly lower in observation group than that in control group (P<0.05). The clinic effective rate in observation group was 81.9%(59/72), which was lower than that of 62.5%(45/72) in control group (P<0.05). The adverse reactions rate was 2.8%(2/72) in control group and 4.2%(3/72) in observation group. There was no significant difference between the two groups (P>0.05). Conclusion Liraglutide can inhibit ERS to decrease blood glucose and lipid in T2DM combined with NAFLD patients, with effectively clinical efficacy and safety.

Key words: Liraglutide, Type 2 diabetes mellitus(T2DM), Non-alcoholic fatty liver disease(NAFLD), Endoplasmic reticulum stress (ERS)

高兰, 刘海蔚, 林璐, 陈开宁. 利拉鲁肽注射液对2型糖尿病合并非酒精性脂肪肝患者内质网应激的影响及其疗效分析[J]. 肝脏, 2020, 25(9): 972-974.

GAO Lan, LIU Hai-wei, LIN Lu, CHEN Kai-ning. Effect of Liraglutide on ERS in T2DM and NAFLD patients and its clinic efficacy[J]. Chinese Hepatolgy, 2020, 25(9): 972-974.

[1]	张进, 张海. FibroScan技术联合血清骨钙素在绝经后女性非酒精性脂肪性肝病患者中的应用[J]. 肝脏, 2020, 25(9): 975-977.
[2]	文琼花, 唐敏云, 魏玉. 血清25(OH)D判断糖尿病合并NAFLD患者继发进展性肝纤维化的应用价值[J]. 肝脏, 2020, 25(8): 810-812.
[3]	张黎雯, 任明星, 薛国昌, 沈琳娜, 夏雪霞, 宋月娟, 夏欢. 肠道菌群失调对肥胖儿童非酒精性脂肪肝发生的影响[J]. 肝脏, 2020, 25(7): 755-758.
[4]	张彬, 张立新, 马婷婷, 苗江虎, 王涛. 2型糖尿病患者血清甲状腺激素水平变化及其与非酒精性脂肪肝的关系[J]. 肝脏, 2020, 25(5): 519-521.
[5]	宋旭光, 何玉冰. 瞬时弹性成像在NAFLD患者肝纤维化和脂肪变性检测中的临床应用[J]. 肝脏, 2020, 25(5): 536-538.
[6]	张荣, 陈婧, 黄江涛, 吕海龙, 杨一邨, 王浩斌, 张抒. 对氧磷酶-1 参与调控非酒精性脂肪肝脂质代谢与胰岛素抵抗作用及机制[J]. 肝脏, 2020, 25(2): 149-154.
[7]	徐丹, 戴秀丽, 张晓梅, 郝咏梅. 2型糖尿病并发非酒精性脂肪性肝病患者血清趋化素、细胞角蛋白18 M30、细胞角蛋白18 M65水平及其临床意义[J]. 肝脏, 2020, 25(1): 46-49.
[8]	王倩, 李秀丽, 杨楠, 王秀萍, 段锦花. GLP-1受体激动剂治疗2型糖尿病合并脂肪肝患者的效果[J]. 肝脏, 2019, 24(9): 1060-1062.
[9]	孙琦, 苏畅, 刘绍群, 雷铭, 沈晓东, 饶荣华, 曹奕鸥. 抗生素联合胸腺肽α1治疗糖尿病合并细菌性肝脓肿的疗效[J]. 肝脏, 2019, 24(9): 1070-1071.
[10]	叶燕, 陈怡, 甘园, 张璇, 王芳. 基于受控衰减参数值变化的综合护理干预在非酒精性脂肪肝中的应用[J]. 肝脏, 2019, 24(8): 942-944.
[11]	许书慧, 郑地明, 钟瑛, 曾少芬. 恩替卡韦对乙型肝炎合并2型糖尿病患者肾功能的影响[J]. 肝脏, 2019, 24(6): 706-708.
[12]	邹琳, 李铁岩, 佘会元. IGF1和IGFBP3在非酒精性脂肪性肝病病程中的表达变化[J]. 肝脏, 2019, 24(5): 521-525.
[13]	彭姗姗, 钟艳丹, 俞海英. 江苏省成人非酒精性脂肪肝患者早期肾损伤状况及影响因素分析[J]. 肝脏, 2019, 24(12): 1425-1426.
[14]	张玉亭, 黄一沁, 陈洁, 保志军. 低脂与低碳水化合物饮食治疗非酒精性脂肪肝的meta分析[J]. 肝脏, 2019, 24(10): 1119-1124.
[15]	王芳, 徐雷, 张囡囡. 血管活性因子及炎性因子在肝硬化上消化道出血合并糖尿病患者异常表达的意义[J]. 肝脏, 2019, 24(1): 78-80.